An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia
- 805 Downloads
The extent and factors associated with codeine use in the community remain poorly understood despite the widespread global use of codeine. The aim of this study was to examine the use of prescription and over-the-counter (OTC) codeine in Australia and identify the geographic and socio-demographic characteristics associated with prescription and OTC codeine use.
National sales data for prescription and OTC codeine (supplied by IMS Health) were used to estimate codeine utilisation (in pack sales and milligrammes) in Australia during 2013, mapped to Australian Bureau of Statistics (ABS) Statistical Local Areas (SLAs) and Remoteness Areas. Socio-demographic characteristics and total population estimates of SLAs were obtained from the ABS. SLA-level data on sex, age distribution, income, occupations involving physical labour and number of pharmacies were included in linear regression analyses to examine their association with total, prescription and OTC codeine use.
In total, 27,780,234 packs of codeine were sold in Australia during 2013, equating to 12,376 kg. OTC codeine preparations accounted for 15,490,207 packs (55.8 %) or 4967.30 kg (40.1 %). Nationally, an estimated 1.24 packs (or 554.10 mg) of codeine were sold per person; utilisation was higher in more remote areas. SLAs with a higher percentage of low-income earning households had the highest rates of prescription codeine use (β 0.16, p < 0.001), whereas SLAs with a higher percentage of males had the highest rates of OTC codeine use (β 0.22, p < 0.001).
Codeine use is common in Australia, with clear distinctions in the geographic and socio-demographic characteristics associated with prescription and OTC codeine use.
KeywordsAnalgesics Opioids Non-prescription drugs Codeine Pharmacoepidemiology Drug utilisation
The authors are very grateful for Billy Henderson’s (Mundipharma) advice and assistance in facilitating access to the data analysed in this study. NG, SN, BL and LD are supported by NHMRC research fellowships (#1091878, #1013803, #1073858 and #1041472). The National Drug and Alcohol Research Centre at UNSW Australia is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grant Fund.
LD, BL and RB originally conceptualised the study and gained access to the data. NG designed the study, undertook part of the data analysis and prepared the first draft of the manuscript. LD and RB led the planning of analyses, SN performed the literature review and EC undertook part of the data analysis. All authors were involved in interpreting data, reviewing analyses and critically revising drafts of the manuscript. All authors approved the final manuscript prior to submission.
Compliance with ethical standards
SN, BL, RB and LD have received untied educational grants from Reckitt Benckiser for post-marketing surveillance of buprenorphine-naloxone tablets and film in the treatment of opioid dependence in Australia, development of an opioid-related behaviour scale and/or a study examining opioid substitution therapy among chronic non-cancer pain patients. RB, BL and LD have received untied educational grant funding from Mundipharma for post-marketing surveillance of Reformulated OxyContin® in Australia.
- 1.International Narcotics Control Board 2015 Narcotic drugs estimated world requirements for 2015—statistics for 2013. https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2014/ND_TR_2014_2_Comments_EN.pdf. Accessed 23 October 2015.
- 3.Degenhardt L, Gisev N, Cama E, Nielsen S, Larance B, Bruno R (2015) The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. Pharmacoepidemiol Drug Saf (in press)Google Scholar
- 4.Therapeutic Guidelines Writing Group (2012) Therapeutic Guidelines: analgesic version 6. Therapeutic Guidelines Limited, North MelbourneGoogle Scholar
- 12.Medani S, Short S, Wall C (2010) Nurofen plus toxicity—what should nephrologists be alert to? Rare Complications of an Increasingly Misused Medication NDT Plus doi: 10.1093/ndtplus/sfq079.Google Scholar
- 19.Therapeutic Goods Administration 2015 Consultation: invitation for public comment - ACMS meeting, July 2015. https://www.tga.gov.au/consultation-invitation/consultation-invitation-public-comment-acms-meeting-july-2015. Accessed 26 October 2015.
- 21.World Health Organization (2003) Introduction to drug utilization research. World Health Organization, GenevaGoogle Scholar
- 24.IBISWorld 2015 IBISWorld Industry Report G4271a Pharmacies in Australia http://clients1.ibisworld.com.au/reports/au/industry/keystatistics.aspx?entid=1878. Accessed 26 October 2015.
- 25.World Health Organization Collaborating Centre for Drugs Statistics Methodology 2013 ATC/DDD Index 2015. Norweigan Institute of Public Health http://www.whocc.no/atc_ddd_index/. Accessed 16 June 2015.
- 26.Australian Bureau of Statistics 2013 1270.0.55.006—Postcode 2011 to Statistical Local Area 2011. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/1270.0.55.006July%202011?OpenDocument. Accessed 31 August 2014.
- 27.Australian Bureau of Statistics 2007 1216.0.15.003—Australian Standard Geographical Classification (ASGC) Remoteness Area Correspondences, 2006. http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/1216.0.15.003Main+Features12006?OpenDocument. Accessed 31 August 2014.
- 28.Australian Bureau of Statistics 2011 1216.0—Australian Standard Geographical Classification (ASGC), July 2011. http://www.abs.gov.au/ausstats/abs@.nsf/mf/1216.0. Accessed 31 August 2014.
- 29.Australian Bureau of Statistics 2014 3235.0—Population by age and sex, regions of Australia, 2013. http://www.abs.gov.au/Ausstats/abs@.nsf/mf/3235.0. Accessed 31 August 2014.
- 30.Australian Bureau of Statistics 2014 Table Builder Pro http://www.abs.gov.au/websitedbs/censushome.nsf/home/tablebuilder?opendocument&navpos=240. Accessed 31 August 2014.
- 31.Maven Marketing 2014 List of Pharmacies and Chemists in Australia http://www.mavenmarketing.com.au/list-of-pharmacies-in-australia/. Accessed 14 March 2015.
- 32.Environmental Systems Research Institute Inc. (2013) ESRI ArcGIS Desktop 10.2. ESRI, California.Google Scholar
- 34.Prunuske JP, St Hill CA, Hager KD, Lemieux AM, Swanoski MT, Anderson GW, Lutfiyya MN (2014) Opioid prescribing patterns for non-malignant chronic pain for rural versus non-rural US adults: a population-based study using 2010 NAMCS data. BMC Health Serv Res 14:563 510.1186/s12913-12014-10563-12918CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Davies EA, O’Mahony MS (2015) Adverse drug reactions in special populations—the elderly. Br J Clin Pharmacol: Published online 22 May 2015. doi: 2010.1111/bcp.12596Google Scholar
- 43.Australian Medicines Handbook (2015). Australian Medicines Handbook Pty Ltd, Adelaide.Google Scholar
- 44.García Rodríguez L, Cattaruzzi C, Troncon M, Agostinis L (1998) Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 158:33–39Google Scholar
- 49.Zebenholzer K, Andree C, Lechner A, Broessner G, Lampl C, Luthringshausen G, Wuschitz A, Obmann S-M, Berek K, Wöber C (2015) Prevalence, management and burden of episodic and chronic headaches—a cross-sectional multicentre study in eight Austrian headache centres. J Headache Pain 16:46. doi: 10.1186/s10194-10015-10531-10197 CrossRefPubMedCentralGoogle Scholar